Most patients lose initial gains in vision despite continued treatment, he added. In a 2022 study, Sodhi’s group identified ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

However, nearly all of the randomized anti-VEGF drug trials for exudative AMD produce vision gains of +8 to +10 letters, suggesting that anti-VEGF monotherapy has hit a therapeutic 'ceiling'.

A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...

The vessels leak fluid or bleed, damaging the retina and causing vision loss. Advertisement To combat this, doctors prescribe ...

The vessels leak fluid or bleed, damaging the retina and causing vision loss. To combat this, doctors prescribe medications ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...